In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuoCort Pharma AB

Division of Takeda Pharmaceutical Co. Ltd.
www.duocort.com

Latest From DuoCort Pharma AB

Deals Shaping the Medical Industry (2/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Medical Device BioPharmaceutical

Deals Shaping The Medical Industry (12/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

DuoCort gains European OK for hydrocortisone replacement therapy

The European Commission has granted marketing authorisation to Swedish drug maker DuoCort Pharma for its dual-release hydrocortisone replacement therapy Plenadren (hydrocortisone, modified-release) as a once-daily oral treatment for adults with adrenal insufficiency – the first new therapy for the condition in 50 years.

Gynecology & Urology Sweden

Viropharma acquires Swedish orphan drug firm DuoCort

ViroPharma, an Exton, Pennsylvania-based firm whose products include treatments for the rare genetic disorder hereditary angioedema (HAE) and for GI infections caused by Staphylococcus aureus and Clostridium difficile, has agreed to pay up to around $165 million to acquire DuoCort Pharma, the Swedish firm awaiting European approval for a drug to treat the rare condition Addison's disease and other conditions causing adrenal insufficiency in adults.

Metabolic Disorders Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Maria Forss, CEO
  • Contact Info
  • DuoCort Pharma AB
    Phone: 42 12 40 20
    Kullagatan 8
    Helsingborg, 252 20
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register